Vanda Pharmaceuticals (VNDA) Financials: History & Chart

Vanda Pharmaceuticals Inc.(VNDA)

Biotechnology · Washington, DC

$4.52-0.06 (-1.31%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Washington, DC

533 employees

www.vandapharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mihael H. Polymeropoulos

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	215.72M	50.53M	51.72M	57.22M	56.26M	52.59M	50.04M	53.19M	47.65M
Cost of Goods Sold	15.49M	3.56M	5.15M	3.83M	2.95M	4.49M	3.52M	2.59M	2.55M
Gross Profit	200.23M	46.97M	46.57M	53.38M	53.30M	48.10M	46.52M	50.59M	45.10M
Gross Profit Margin	92.8%	93.0%	90.0%	93.3%	94.7%	91.5%	93.0%	95.1%	94.6%
Total Operating Expenses	385.90M	110.78M	96.80M	93.74M	84.59M	86.61M	91.07M	60.87M	56.10M
Research & Development	116.96M	36.95M	28.43M	29.01M	22.56M	21.99M	35.71M	19.84M	16.78M
Selling, General & Administrative	263.45M	71.84M	68.36M	62.98M	60.27M	64.62M	50.08M	39.28M	37.57M
Operating Income (EBIT)	-185.67M	-63.81M	-50.22M	-40.35M	-31.28M	-38.50M	-44.55M	-10.28M	-11.00M
Operating Margin	-86.1%	-126.3%	-97.1%	-70.5%	-55.6%	-73.2%	-89.0%	-19.3%	-23.1%
Income Before Tax (EBT)	-177.20M	-62.38M	-48.42M	-38.00M	-28.39M	-34.89M	-37.37M	-6.50M	-6.24M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	8.47M	1.43M	1.80M	2.35M	2.89M	3.62M	7.18M	3.78M	4.76M
Net Income	-274.85M	-62.51M	-48.57M	-141.19M	-22.59M	-27.21M	-29.49M	-4.91M	-5.32M
Income Tax Expense	97.65M	129K	143K	103.19M	-5.80M	-7.68M	-7.87M	-1.58M	-920K
Net Profit Margin	-127.4%	-123.7%	-93.9%	-246.8%	-40.1%	-51.7%	-58.9%	-9.2%	-11.2%
EBITDA	-172.24M	-61.82M	-46.70M	-34.49M	-29.23M	-36.49M	-43.57M	-8.31M	-9.03M
EBITDA Margin	-79.8%	-122.3%	-90.3%	-60.3%	-52.0%	-69.4%	-87.1%	-15.6%	-19.0%
Depreciation & Amortization	13.43M	1.99M	3.53M	5.86M	2.05M	2.02M	980K	1.97M	1.97M
EPS Basic	-4.63	-1.04	-0.82	-2.39	-0.38	-0.46	-0.50	-0.08	-0.09
EPS Diluted	-4.63	-1.04	-0.82	-2.39	-0.38	-0.46	-0.50	-0.08	-0.09
Weighted Average Basic Shares	60.23M	60.23M	59.46M	59.10M	58.87M	58.99M	58.53M	58.31M	58.26M
Weighted Average Diluted Shares	60.23M	60.23M	59.46M	59.10M	58.87M	58.99M	58.53M	58.31M	58.26M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	216.10M	198.77M	192.64M	254.38M	268.68M	248.17M	227.19M	193.12M
Cost of Goods Sold	13.04M	11.31M	14.80M	24.28M	25.63M	23.36M	24.49M	20.51M
Gross Profit	203.06M	187.46M	177.84M	230.10M	243.05M	224.80M	202.70M	172.61M
Gross Profit Margin	94.0%	94.3%	92.3%	90.5%	90.5%	90.6%	89.2%	89.4%
Total Operating Expenses	354.23M	228.12M	191.80M	223.77M	200.89M	197.56M	179.89M	150.87M
Research & Development	109.27M	74.43M	76.82M	85.77M	75.36M	55.58M	48.65M	43.59M
Selling, General & Administrative	237.95M	146.41M	112.88M	136.49M	124.05M	140.51M	129.74M	105.75M
Operating Income (EBIT)	-151.17M	-40.66M	-13.95M	6.33M	42.16M	27.24M	22.81M	21.74M
Operating Margin	-70.0%	-20.5%	-7.2%	2.5%	15.7%	11.0%	10.0%	11.3%
Income Before Tax (EBT)	-138.65M	-22.92M	6.34M	11.30M	42.36M	31.66M	29.03M	25.35M
Interest Income	N/A	N/A	N/A	N/A	199K	4.42M	6.22M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	12.52M	17.74M	20.29M	4.97M	199K	4.42M	6.22M	3.61M
Net Income	-220.47M	-18.90M	2.51M	6.28M	33.15M	23.34M	115.55M	25.21M
Income Tax Expense	81.83M	-4.02M	3.83M	5.03M	9.21M	8.32M	-86.53M	138K
Net Profit Margin	-102.0%	-9.5%	1.3%	2.5%	12.3%	9.4%	50.9%	13.1%
EBITDA	-139.25M	-32.53M	-10.94M	9.06M	45.01M	30.10M	25.70M	24.69M
EBITDA Margin	-64.4%	-16.4%	-5.7%	3.6%	16.8%	12.1%	11.3%	12.8%
Depreciation & Amortization	11.92M	8.13M	3.01M	2.73M	2.84M	2.86M	2.89M	2.96M
EPS Basic	-3.74	-0.32	0.04	0.11	0.60	0.43	2.17	0.50
EPS Diluted	-3.74	-0.32	0.04	0.11	0.58	0.42	2.11	0.48
Weighted Average Basic Shares	58.93M	58.15M	57.38M	56.46M	55.55M	54.43M	53.14M	50.86M
Weighted Average Diluted Shares	58.93M	58.15M	57.56M	56.98M	56.92M	55.19M	54.85M	53.05M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.